Post-marketing open-label observational clinical study to determine the efficacy of Micon Gold Capsule in Type 2 Diabetes Mellitus

Med Pharma CRO0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年3月6日

试验速览

暂无简介。

•1.Patients 25 years or older, with Type 2 Diabetes Mellitus confirmed by WHO criteria for type 2 diabetes
•2.Patients freshly diagnosed as diabetics or those who were on oral hypoglycemic agents without insulin
•3.Patients willing to give written informed consent.
•4.Patients are fit and no need for any hospital administration.
•5.Patients willing to perform all study related procedures including the use of study medicine, allow the physical and Biochemical tests and willing to document symptoms and medication.

•1.Patients with renal impairment.
•2.Patients will be also excluded if they have poorly controlled diabetes mellitus.
•3.Female patients who are pregnant.
•4.Unstable medical or psychiatric illness.
•5.Chronic & acute disorders requiring hospital admission.
•6.Known HIV-positive, Hepatitis B or C status.
•7.Inability to carry out visits for the study.
•8.Inability to maintain current medication regimen.
•9.Inability or unwillingness to participate in all components of the study.

发起方

Med Pharma CRO